Bcıı—RFLP profiles for serum amiloid A1 and mutated MEFV gene prevalence in chronic renal failure patients requiring long-term hemodialysis

References

• Palmer SC, Vecchio M, Craig JC, et al. Association between depression and death in people with CKD: A meta-analysis of cohort studies. Am J Kidney Dis. 2013;62(3):493–505
   PubMed Web of Science ®Google Scholar
• Altiparmak MR, Seyahi N, Trabulus S, et al. Applicability of a different estimation equation of glomerular filtration rate in Turkey. Ren Fail. 2013;35(8):1116–1123
   PubMed Web of Science ®Google Scholar
• Lewis R. An overview of chronic kidney disease in older people. Nurs Older People. 2013;25(10):31–38
   PubMedGoogle Scholar
• Chandna S, Da Silva-Gane M, Marshall C, Warwicker P, Greenwood RN, Farrington K. Survival of elderly patients with stage 5CKD: Comparison of conservative management and renal replacement therapy. Nephrol Dial Transpl. 2001;26(5):1608–1614
   Google Scholar
• Satta E, Perna AF, Lombardi C, et al. Hyperhomocysteinemia in chronic renal failure. G Ital Nefrol. 2006;23(5):480–489
   PubMedGoogle Scholar
• Miao XH, Wang CG, Hu BQ, Li A, Chen CB, Song WQ. TGF-beta1 immunohistochemistry and promoter methylation in chronic renal failure rats treated with Uremic Clearance Granules. Folia Histochem Cytobiol. 2010;48(2):284–291
   PubMedGoogle Scholar
• Whyte MP, Leelawattana R, Reinus WR, Yang C, Mumm S, Novack DV. Acute severe hypercalcemia after traumatic fractures and immobilization in hypophosphatasia complicated by chronic renal failure. J Clin Endocrinol Metab. 2013;98(12):4606–4612
   PubMedGoogle Scholar
• Deltas C, Pierides A, Voskarides K. Molecular genetics of familial hematuric diseases. Nephrol Dial Transplant. 2013;28(12):2946–2960
   PubMedGoogle Scholar
• Aydin B, Ipek MS, Ozaltin F, et al. A novel mutation of laminin β-2 gene in Pierson syndrome manifested with nephrotic syndrome in the early neonatal period. Genet Couns. 2013;24(2):141–147
   PubMedGoogle Scholar
• Ben-Chetrit E, Backenroth R. Amyloidosis induced, end stage renal disease in patients with familial Mediterranean fever is highly associated with point mutations in the MEFV gene. Ann Rheum Dis. 2001;60(2):146–149
   PubMedGoogle Scholar
• Dember LM. Amyloidosis-associated kidney disease. J Am Soc Nephrol. 2006;17:3458–3471
   PubMed Web of Science ®Google Scholar
• Eirin A, Irazabal MV, Gertz MA, et al. Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascularlimited deposition in the kidney. Nephrol Dial Transplant. 2012;27:1097–1101
   PubMed Web of Science ®Google Scholar
• Cerquaglia C, Diaco M, Nucera G, La Regina M, Montalto M, Manna R. Pharmacological and clinical basis of treatment of familial Mediterranean fever (FMF) with colchicine or analogues: An update. Curr Drug Targets Inflam Allergy. 2005;4:117–124
   PubMedGoogle Scholar
• Tang W, McDonald SP, Hawley CM, et al. End-stage renal failure due to amyloidosis: Outcomes in 490 ANZDATA registry cases. Nephrol Dial Transplant. 2013;28(2):455–461
   PubMed Web of Science ®Google Scholar
• Delibaş A, Oner A, Balci B, et al. Genetic risk factors of amyloidogenesis in familial Mediterranean fever. Am J Nephrol. 2005;25(5):434–440
   PubMedGoogle Scholar
• Ajiro J, Narita I, Sato F, et al. SAA1 gene polymorphisms and the risk of AA amyloidosis in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2006;16(5):294–299
   PubMedGoogle Scholar
• Baba S, Masago SA, Takahashi T, et al. A novel allelic variant of serum amyloid A, SAA1 gamma: Genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA-amyloidosis. Hum Mol Genet. 1995;4(6):1083–1087
   PubMed Web of Science ®Google Scholar
• Moriguchi M, Terai C, Koseki Y, et al. Influence of genotypes at SAA1 and SAA2 loci on the development and the length of latent period of secondary AA-amyloidosis in patients with rheumatoid arthritis. Hum Genet. 1999;105(4):360–366
   PubMed Web of Science ®Google Scholar
• Booth DR, Booth SE, Gillmore JD, Hawkins PN, Pepys MB. SAA1 alleles as risk factors in reactive systemic AA amyloidosis. Amyloid. 1998;5(4):262–265
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356(23):2361–2371
   PubMed Web of Science ®Google Scholar
• Simons JP, Al-Shawi R, Ellmerich S, et al. Pathogenetic mechanisms of amyloid A amyloidosis. Proc Natl Acad Sci USA. 2013;110(40):16115–16120
   PubMed Web of Science ®Google Scholar
• Gershoni-Baruch R, Brik R, Zacks N, Shinawi M, Lidar M, Livneh A. The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum. 2003;48:1149–1155
   PubMed Web of Science ®Google Scholar
• Grateau G. The relation between familial Mediterranean fever and amyloidosis. Curr Opin Rheumatol. 2000;12(1):61–64
   PubMedGoogle Scholar
• Ozdemir O, Sezgin I, Kurtulgan KH, et al. Prevalence of known mutations in the MEFV gene in a population screening with high rate of carriers. Mol Biol Rep. 2011;38(5):3195–3200
   PubMedGoogle Scholar
• Cazeneuve C, Ajrapetyan H, Papin S, et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. Am J Hum Genet. 2000;67:1136–1143
   PubMed Web of Science ®Google Scholar
• Hallan SI, Orth SR. Smoking is a risk factor in the progression to kidney failure. Kidney Int. 2011;80(5):516–523
   PubMedGoogle Scholar
• Sezgin I, Koksal B, Bagci G, Kurtulgan HK, Ozdemir O. CCR2 polymorphism in chronic renal failure patients requiring long-term hemodialysis. Intern Med. 2011;50:2457–2461
   PubMedGoogle Scholar
• De Serres SA, Varghese JC, Levin A. Biomarkers in native and transplant kidneys: Opportunities to improve prediction of outcomes in chronic kidney disease. Curr Opin Nephrol Hypertens. 2012;21(6):619–627
   PubMedGoogle Scholar
• Buraczynska M, Ksiazek P, Wacinski P, Zukowski P, Dragan M, Bednarek-Skublewska A. Complement receptor 1 gene polymorphism and cardiovascular disease in dialyzed end-stage renal disease patients. Hum Immunol. 2010;71(9):878–882
   PubMedGoogle Scholar
• Zhou TB, Yin SS. Association of endothelial nitric oxide synthase Glu298Asp gene polymorphism with the risk of end-stage renal disease. Ren Fail. 2013;35(4):573–578
   PubMed Web of Science ®Google Scholar
• Klai S, Fekih-Mrissa N, Ghachem A, et al. Thrombophilic disorders: A real threat to patients with end-stage renal disease on hemodialysis and at the time of renal transplantation. Blood Coagul Fibrinol. 2012;23(5):406–410
   PubMedGoogle Scholar
• Medlej-Hashim M, Delague V, Chouery E, et al. Amyloidosis in familial Mediterranean fever patients: Correlation with MEFV genotype and SAA1 and MICA polymorphisms effects. BMC Med Genet. 2004;5(4):1–6
   PubMedGoogle Scholar
• Cazeneuve C, Ajrapetyan H, Papin S, et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. Am J Hum Genet. 2000;67(5):1136–1143
   PubMed Web of Science ®Google Scholar
• Gershoni-Baruch R, Brik R, Zacks N, Shinawi M, Lidar M, Livneh A. The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum. 2003;48(4):1149–1155
   PubMedGoogle Scholar